Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
22 mai 2024 08h00 HE
|
Indaptus Therapeutics
First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune systemsInvestigational package of broad immune agonists derived from Gram-negative bacteria...
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
04 mars 2024 07h30 HE
|
Indaptus Therapeutics
• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data...
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
06 nov. 2023 16h01 HE
|
Indaptus Therapeutics
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023...
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
06 nov. 2023 08h00 HE
|
Indaptus Therapeutics
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to...
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
31 oct. 2023 09h01 HE
|
Indaptus Therapeutics
Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP)...
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
19 sept. 2023 08h00 HE
|
Indaptus Therapeutics
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to...
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
17 mars 2023 08h00 HE
|
Indaptus Therapeutics
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth quarter and fiscal year ended...
Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
07 mars 2023 08h05 HE
|
Indaptus Therapeutics
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
13 déc. 2022 07h30 HE
|
Indaptus Therapeutics
NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...